Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 1.00 |
| ▸ | LHCGR | P22888 | 4/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.78 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
| ▸ | HTR2C | P28335 | 1/20 | 0.78 |
| ▸ | HTR2B | P41595 | 1/20 | 0.78 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067195 | 1.00 | TRPM8 (1.00) | TRPM8LHCGROPRK1TMEM97SIGMAR1 | |
| SCHEMBL4183269 | 0.86 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3960709 | 0.86 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3960706 | 0.86 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL4062190 | 0.85 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3956643 | 0.85 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3958128 | 0.85 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL32048897 | 0.84 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3052759 | 0.84 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL31518948 | 0.84 | TRPM8 (1.00) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | claimed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TRPM8 33/4885LHCGR 1595/4885OPRK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.